蘑菇AV

D2C shoppers want fast delivery speed: Survey shows they are less interested in the story behind a brand and more concerned about basic operational execution.

Eli Lilly adds Alzheimer鈥檚 treatments, resources to D2C platform: Lilly is progressing its D2C online offerings even as lawmakers ramp up scrutiny of drugmaker-telehealth partnerships.

Healthcare and pharma companies are embracing D2C business models to get their medications, treatments, and services to more consumers without industry middlemen restricting access. Concurrently, patients are becoming more price-conscious healthcare shoppers, propelling more D2C activity next year.

Novo Nordisk launches D2C platform, drops price of Wegovy for cash-pay patients: The move could start a marketing showdown鈥攁nd possible price war鈥攂etween Novo and Lilly.

Rapidly growing healthcare providers are reinvesting in online marketing: Incumbents must embrace social and search marketing to ward off competition from telehealth and D2C providers.

Warby Parker joins forces with Target: The D2C eyewear brand will open five shop-in-shops as it doubles down on physical retail.

Lawmakers investigate telehealth tie-ups with pharma: Despite more scrutiny over potential conflicts of interest, we expect even more Big Pharma D2C launches this year.

Senators reintroduce Drug-price Transparency for Consumers Act: If passed, the Act could empower patients to make informed decisions about their healthcare amid a torrent of direct-to-consumer drug ads.

Sanofi鈥檚 Opella secures FDA nod to pursue OTC Cialis study: If Cialis鈥� shift from a prescription drug to over-the-counter product comes to fruition, both consumers and D2C retailers could benefit.

Could Trump鈥檚 second term include a ban on D2C pharma ads? We examine the likelihood of a ban and explore what more oversight of drug ads on TV means for pharma marketers.

Healthcare and pharma companies will lean further into D2C in 2025: They鈥檙e cutting out health insurers and PBMs that bottleneck patient access to their products and services. But the industry鈥檚 push into D2C won鈥檛 be met without challenges.

The battle between Big Pharma and D2C weight loss drug sellers will intensify in 2025: We explore the competitive GLP-1 drug market and detail what鈥檚 at stake for drugmakers and D2C companies selling compounded weight loss medications.

RFK Jr.鈥檚 pharmaceutical ad ban could affect $22 billion in ad spending: A business-friendly Trump administration could hamper RFK鈥檚 plans to cut D2C advertising.

Nike's recent struggles highlight the risks of an ill-timed shift to direct-to-consumer (D2C) sales. The sportswear giant's sales slumped 10% YoY for the quarter ending August 31 as competitors gained market share.

On Holdings鈥檚 sales jumped 34% in Q3: The upstart鈥檚 efforts to boost brand awareness gave lucrative direct-to-consumer sales a lift.